{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:07:37Z","timestamp":1786118857597,"version":"build-2736575974"},"reference-count":55,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Surgical Clinics of North America"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.suc.2026.03.003","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T19:58:35Z","timestamp":1779911915000},"page":"465-479","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Genetics, Screening, and Risk-reducing Interventions for Breast Cancer"],"prefix":"10.1016","volume":"106","author":[{"given":"Julie","family":"Le","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Madlensky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara A.","family":"Retson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara M.","family":"Grossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.suc.2026.03.003_bib2","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1086\/375033","article-title":"Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies","volume":"72","author":"Antoniou","year":"2003","journal-title":"Am J Hum Genet"},{"issue":"5","key":"10.1016\/j.suc.2026.03.003_bib3","first-page":"1059","article-title":"Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families","volume":"60","author":"Levy-Lahad","year":"1997","journal-title":"Am J Hum Genet"},{"issue":"1","key":"10.1016\/j.suc.2026.03.003_bib4","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s10549-011-1544-9","article-title":"Prevalence of BRCA1\/2 mutations in sporadic breast\/ovarian cancer patients and identification of a novel de novo BRCA1 mutation in a patient diagnosed with late onset breast and ovarian cancer: implications for genetic testing","volume":"132","author":"De Leeneer","year":"2012","journal-title":"Breast Cancer Res Treat"},{"issue":"23","key":"10.1016\/j.suc.2026.03.003_bib5","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1001\/jama.2017.7112","article-title":"Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers","volume":"317","author":"Kuchenbaecker","year":"2017","journal-title":"JAMA"},{"issue":"25","key":"10.1016\/j.suc.2026.03.003_bib6","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","article-title":"Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer","volume":"384","author":"Tutt","year":"2021","journal-title":"N Engl J Med"},{"issue":"7471","key":"10.1016\/j.suc.2026.03.003_bib7","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/nature12634","article-title":"Mutational landscape and significance across 12 major cancer types","volume":"502","author":"Kandoth","year":"2013","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.suc.2026.03.003_bib8","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1200\/JCO.18.00331","article-title":"Managing clonal hematopoiesis in patients with solid tumors","volume":"37","author":"Bolton","year":"2019","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.suc.2026.03.003_bib9","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/gim.2017.196","article-title":"Somatic TP53 variants frequently confound germ-line testing results","volume":"20","author":"Weitzel","year":"2018","journal-title":"Genet Med"},{"issue":"6465","key":"10.1016\/j.suc.2026.03.003_bib10","doi-asserted-by":"crossref","DOI":"10.1126\/science.aan4673","article-title":"Clonal hematopoiesis in human aging and disease","volume":"366","author":"Jaiswal","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.suc.2026.03.003_bib11","series-title":"GeneReviews\u00ae","article-title":"Li-Fraumeni Syndrome","author":"Schneider","year":"1999"},{"issue":"4985","key":"10.1016\/j.suc.2026.03.003_bib12","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1126\/science.1978757","article-title":"Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms","volume":"250","author":"Malkin","year":"1990","journal-title":"Science"},{"issue":"23","key":"10.1016\/j.suc.2026.03.003_bib13","doi-asserted-by":"crossref","first-page":"3673","DOI":"10.1002\/cncr.30248","article-title":"Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li-Fraumeni syndrome cohort","volume":"122","author":"Mai","year":"2016","journal-title":"Cancer"},{"issue":"21","key":"10.1016\/j.suc.2026.03.003_bib14","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1200\/JCO.2014.59.5728","article-title":"Revisiting Li-Fraumeni syndrome from TP53 mutation carriers","volume":"33","author":"Bougeard","year":"2015","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.suc.2026.03.003_bib15","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1158\/1078-0432.CCR-17-0408","article-title":"Cancer screening recommendations for individuals with Li-Fraumeni syndrome","volume":"23","author":"Kratz","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.suc.2026.03.003_bib16","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/S1470-2045(16)30249-2","article-title":"Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: 11 year follow-up of a prospective observational study","volume":"17","author":"Villani","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.suc.2026.03.003_bib17","unstructured":"National Cancer Institute. Definition of PTEN gene. NCI Dictionary of Cancer Terms. Available at: https:\/\/www.cancer.gov\/publications\/dictionaries\/cancer-terms (Accessed 8 March 2026)."},{"key":"10.1016\/j.suc.2026.03.003_bib18","series-title":"GeneReviews\u00ae","article-title":"PTEN hamartoma tumor syndrome","author":"Yehia","year":"2001"},{"issue":"2","key":"10.1016\/j.suc.2026.03.003_bib19","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1158\/1078-0432.CCR-11-2283","article-title":"Lifetime cancer risks in individuals with germline PTEN mutations","volume":"18","author":"Tan","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.suc.2026.03.003_bib20","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/ajg.2014.435","article-title":"ACG clinical guideline: genetic testing and management of hereditary gastrointestinal cancer syndromes","volume":"110","author":"Syngal","year":"2015","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"10.1016\/j.suc.2026.03.003_bib21","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1136\/jmedgenet-2015-103094","article-title":"Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline CDH1 mutation carriers","volume":"52","author":"van der Post","year":"2015","journal-title":"J Med Genet"},{"issue":"1","key":"10.1016\/j.suc.2026.03.003_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.gim.2024.101243","article-title":"Management of individuals with heterozygous germline pathogenic variants in ATM: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG)","volume":"27","author":"Pal","year":"2025","journal-title":"Genet Med"},{"issue":"10","key":"10.1016\/j.suc.2026.03.003_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.gim.2023.100870","article-title":"Management of individuals with germline pathogenic\/likely pathogenic variants in CHEK2: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG)","volume":"25","author":"Hanson","year":"2023","journal-title":"Genet Med"},{"issue":"28","key":"10.1016\/j.suc.2026.03.003_bib24","doi-asserted-by":"crossref","first-page":"3747","DOI":"10.1200\/JCO.2010.34.0778","article-title":"Risk of breast cancer in women with a CHEK2 mutation with and without a family history of breast cancer","volume":"29","author":"Cybulski","year":"2011","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.suc.2026.03.003_bib25","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1038\/s41436-021-01151-8","article-title":"Management of individuals with germline variants in PALB2: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG)","volume":"23","author":"Tischkowitz","year":"2021","journal-title":"Genet Med"},{"issue":"6","key":"10.1016\/j.suc.2026.03.003_bib26","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/S1470-2045(15)70142-7","article-title":"Clinical outcomes in women with breast cancer and a PALB2 mutation: a prospective cohort analysis","volume":"16","author":"Cybulski","year":"2015","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.suc.2026.03.003_bib27","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1200\/JCO.22.01239","article-title":"Contralateral breast cancer risk among carriers of germline pathogenic variants in ATM, BRCA1, BRCA2, CHEK2, and PALB2","volume":"41","author":"Yadav","year":"2023","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.suc.2026.03.003_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.gim.2025.101557","article-title":"Management of individuals with heterozygous germline pathogenic variants in RAD51C, RAD51D, and BRIP1: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG)","volume":"27","author":"Ngeow","year":"2025","journal-title":"Genet Med"},{"issue":"11","key":"10.1016\/j.suc.2026.03.003_bib29","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines13112764","article-title":"Characterization of a genetic variant in BARD1 in subjects undergoing germline testing for hereditary tumors","volume":"13","author":"Marino","year":"2025","journal-title":"Biomedicines"},{"issue":"5","key":"10.1016\/j.suc.2026.03.003_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.gim.2023.100803","article-title":"The clinical application of polygenic risk scores: a points to consider statement of the American College of Medical Genetics and Genomics (ACMG)","volume":"25","author":"Abu-El-Haija","year":"2023","journal-title":"Genet Med"},{"issue":"24","key":"10.1016\/j.suc.2026.03.003_bib31","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1093\/jnci\/81.24.1879","article-title":"Projecting individualized probabilities of developing breast cancer for white females who are being examined annually","volume":"81","author":"Gail","year":"1989","journal-title":"J Natl Cancer Inst"},{"issue":"18","key":"10.1016\/j.suc.2026.03.003_bib32","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1093\/jnci\/90.18.1371","article-title":"Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study","volume":"90","author":"Fisher","year":"1998","journal-title":"J Natl Cancer Inst"},{"issue":"23","key":"10.1016\/j.suc.2026.03.003_bib33","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.1200\/JCO.2013.49.3122","article-title":"Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline","volume":"31","author":"Visvanathan","year":"2013","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.suc.2026.03.003_bib34","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1136\/jmg.40.11.807","article-title":"Evaluation of breast cancer risk assessment packages in the family history evaluation and screening programme","volume":"40","author":"Amir","year":"2003","journal-title":"J Med Genet"},{"issue":"1","key":"10.1016\/j.suc.2026.03.003_bib35","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s13058-020-01340-4","article-title":"Mammographic density change in a cohort of premenopausal women receiving tamoxifen for breast cancer prevention over 5 years","volume":"22","author":"Brentnall","year":"2020","journal-title":"Breast Cancer Res"},{"issue":"2","key":"10.1016\/j.suc.2026.03.003_bib36","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1148\/radiol.2021204581","article-title":"Digital mammography and breast tomosynthesis performance in women with a personal history of breast cancer, 2007-2016","volume":"300","author":"Lee","year":"2021","journal-title":"Radiology"},{"issue":"7","key":"10.1016\/j.suc.2026.03.003_bib37","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1002\/sim.1668","article-title":"A breast cancer prediction model incorporating familial and personal risk factors","volume":"23","author":"Tyrer","year":"2004","journal-title":"Stat Med"},{"key":"10.1016\/j.suc.2026.03.003_bib38","author":"Society"},{"issue":"9","key":"10.1016\/j.suc.2026.03.003_bib39","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.jacr.2023.04.002","article-title":"Breast cancer screening for women at higher-than-average risk: updated recommendations from the ACR","volume":"20","author":"Monticciolo","year":"2023","journal-title":"J Am Coll Radiol"},{"issue":"7","key":"10.1016\/j.suc.2026.03.003_bib40","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv124","article-title":"Practical problems with clinical guidelines for breast cancer prevention based on remaining lifetime risk","volume":"107","author":"Quante","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.suc.2026.03.003_bib41","author":"Network"},{"key":"10.1016\/j.suc.2026.03.003_bib42","author":"Gynecology"},{"key":"10.1016\/j.suc.2026.03.003_bib43","author":"Force"},{"issue":"8","key":"10.1016\/j.suc.2026.03.003_bib44","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/S1470-2045(19)30275-X","article-title":"MRI versus mammography for breast cancer screening in women with familial risk (FaMRIsc): a multicentre, randomised, controlled trial","volume":"20","author":"Saadatmand","year":"2019","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.suc.2026.03.003_bib45","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1200\/JCO.2014.56.8626","article-title":"Triple-modality screening trial for familial breast cancer underlines the importance of magnetic resonance imaging and questions the role of mammography and ultrasound regardless of patient mutation status, age, and breast density","volume":"33","author":"Riedl","year":"2015","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.suc.2026.03.003_bib46","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1148\/radiol.2019181136","article-title":"Performance of screening breast MRI across women with different elevated breast cancer risk indications","volume":"292","author":"Sippo","year":"2019","journal-title":"Radiology"},{"issue":"4","key":"10.1016\/j.suc.2026.03.003_bib47","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1001\/jamaoncol.2021.6204","article-title":"Breast cancer screening strategies for women with ATM, CHEK2, and PALB2 pathogenic variants: a comparative modeling analysis","volume":"8","author":"Lowry","year":"2022","journal-title":"JAMA Oncol"},{"issue":"22","key":"10.1016\/j.suc.2026.03.003_bib48","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1903986","article-title":"Supplemental MRI Screening for women with extremely dense breast tissue","volume":"381","author":"Bakker","year":"2019","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.suc.2026.03.003_bib49","doi-asserted-by":"crossref","first-page":"4036","DOI":"10.1007\/s00330-022-08617-6","article-title":"Breast cancer screening in women with extremely dense breasts recommendations of the European Society of breast Imaging (EUSOBI)","volume":"32","author":"Mann","year":"2022","journal-title":"Eur Radiol"},{"issue":"8","key":"10.1016\/j.suc.2026.03.003_bib50","doi-asserted-by":"crossref","DOI":"10.3390\/diagnostics12081890","article-title":"Contrast-enhanced mammography versus breast magnetic resonance imaging: a systematic review and meta-analysis","volume":"12","author":"Gelardi","year":"2022","journal-title":"Diagnostics"},{"issue":"4","key":"10.1016\/j.suc.2026.03.003_bib51","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1093\/jbi\/wbz055","article-title":"Screening breast ultrasound using handheld or automated technique in women with dense breasts","volume":"1","author":"Berg","year":"2019","journal-title":"J Breast Imaging"},{"issue":"4","key":"10.1016\/j.suc.2026.03.003_bib52","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv367","article-title":"Ultrasound as the primary screening test for breast cancer: analysis from ACRIN 6666","volume":"108","author":"Berg","year":"2016","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"10.1016\/j.suc.2026.03.003_bib53","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.amjsurg.2016.06.010","article-title":"Risk reduction and survival benefit of prophylactic surgery in BRCA mutation carriers, a systematic review","volume":"212","author":"Ludwig","year":"2016","journal-title":"Am J Surg"},{"issue":"2","key":"10.1016\/j.suc.2026.03.003_bib54","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1245\/s10434-024-16484-2","article-title":"Society of surgical oncology breast disease site working group statement on bilateral risk-reducing mastectomy: indications, outcomes, and risks","volume":"32","author":"Singh","year":"2025","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"10.1016\/j.suc.2026.03.003_bib55","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1245\/s10434-025-18814-4","article-title":"Sentinel lymph node biopsy for prophylactic mastectomy: necessary precaution or unnecessary procedure?","volume":"33","author":"Shern","year":"2026","journal-title":"Ann Surg Oncol"},{"issue":"23","key":"10.1016\/j.suc.2026.03.003_bib56","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1001\/jama.295.23.joc60074","article-title":"Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial","volume":"295","author":"Vogel","year":"2006","journal-title":"JAMA"}],"container-title":["Surgical Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039610926000319?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039610926000319?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T16:56:18Z","timestamp":1786035378000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0039610926000319"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":55,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S0039610926000319"],"URL":"https:\/\/doi.org\/10.1016\/j.suc.2026.03.003","relation":{},"ISSN":["0039-6109"],"issn-type":[{"value":"0039-6109","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genetics, Screening, and Risk-reducing Interventions for Breast Cancer","name":"articletitle","label":"Article Title"},{"value":"Surgical Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.suc.2026.03.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}